Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 166188-11-0 tyrosinase(206-214),human in China, also supports custom service. Welcome to wholesale bulk high quality cas 166188-11-0 tyrosinase(206-214),human from our factory. Contact us for more details.
| Description | Melanocyte differentiation antigen tyrosinase residues 206–214, an HLA-restricted CD8+ T epitope; used for melanoma tumor immunology, vaccines and T-cell responses. |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure (Sequence) | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| Tyrosinase (206-214), human (human tyrosinase residues 206–214, 9-mer, AFLPWHRLF) | Tyrosinase 206-214; Tyr206-214; AFLPWHRLF; human tyrosinase CTL epitope; CAS 166188-11-0 | tumor antigen, melanoma, tyrosinase, CTL epitope, HLA-A*2402, cancer vaccine, CD8+ T cell | Linear 9-mer, H-Ala-Phe-Leu-Pro-Trp-His-Arg-Leu-Phe-OH; free N-terminal Ala and free C-terminal Phe carboxylic acid; HLA-A*2402-restricted epitope with Phe anchors at P2 and P9 fitting the B- and F-pockets of the HLA peptide-binding groove; contains Trp×1, His×1, Arg×1; hydrophobic residues (A/F/L/P/W/L/F) ~67% of the sequence, overall hydrophobic | C61H83N15O10 | 1185.64 | 1186.42 | TFA salt (trifluoroacetate salt, explicitly stated by CPC Scientific); CAS 166188-11-0 | 9 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-TYRO206-01 | White to off-white powder (TFA salt, hygroscopic) | Store at −20°C, sealed, desiccated, protected from light; flush with Ar/N2, aliquot to avoid repeated freeze-thaw; ~2 years. TFA salt is highly hygroscopic - keep in a desiccator with silica gel; the Trp residue requires light protection throughout. | 2–8°C, desiccated, dark, for ~1 week; working aliquots at −80°C, protected from light; ship on dry ice; avoid room-temperature exposure. | Poorly water-soluble (~67% hydrophobic residues); cannot be directly dissolved in aqueous buffer. First dissolve in a small volume of DMSO (≤10% final) or DMF to 1–2 mM with sonication/vortexing, then dilute with PBS or serum-free medium to working concentration. Keep protected from light at all steps due to Trp; solution stable ≤24 h at 4°C dark, or aliquot and store at −80°C dark; prepare fresh and avoid repeated freeze-thaw. | TFA salt stable ~2 years at −20°C, sealed, desiccated, dark. TFA salt is highly hygroscopic - store in a desiccator under inert gas. Contains Trp×1, sensitive to oxidation and photo-degradation - keep dark; do not co-store with oxidants. |
Functional Description
| Product Code | Frontend Short Summary | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Receptors |
| PEP-TYRO206-01 | Human tyrosinase (UniProt P14679) residues 206–214, an HLA-A*2402-restricted CD8+ CTL epitope (AFLPWHRLF, 9-mer) with double Phe anchors at P2/P9. A classic melanoma differentiation-antigen peptide for cancer vaccines and MHC-tetramer staining; white TFA powder, DMSO-assisted dissolution, light-protected throughout; for tumor immunology and melanoma CTL-response assays. | Human tyrosinase (UniProt P14679) is the rate-limiting enzyme of melanin synthesis in melanocytes and one of the most widely studied melanocyte differentiation antigens in melanoma. Its residues 206–214, the 9-mer AFLPWHRLF, is presented by HLA-A*2402 (HLA-A24) and is specifically recognized by CD8+ cytotoxic T lymphocytes (CTLs) in peripheral blood and tumor-infiltrating lymphocytes (TILs) of melanoma patients. The peptide uses Phe as dual hydrophobic anchors at P2 and P9, fitting into the B- and F-pockets of the HLA-A*2402 binding groove, matching the HLA-A*2402 peptide-binding motif (P2 = Tyr/Phe/Leu; P9 = Phe/Leu). The epitope has been used since the late 1990s for: (1) cancer vaccine and adoptive T-cell therapy studies in HLA-A*2402-positive melanoma patients; (2) HLA-A*2402/AFLPWHRLF tetramer staining to quantify and FACS-sort antigen-specific CD8+ T cells; (3) in vitro CTL induction, ELISpot/ICS IFN-γ assays; (4) TCR discovery and TCR-T/chimeric receptor screening. Because HLA-A*2402 is carried by >20% of East Asian populations (including Chinese, Japanese, and Koreans), this epitope is particularly valuable for melanoma immunotherapy research in Asian cohorts. | tumor immunology, melanoma, cancer vaccine, HLA-A*2402-restricted CTL epitope, CD8+ T-cell response, peptide-MHC tetramer staining, ELISpot/ICS, TCR discovery, adoptive T-cell therapy | HLA-A*2402 (HLA-A24) antigen-presenting molecule; human tyrosinase (UniProt P14679, melanogenesis rate-limiting enzyme); CD8+ cytotoxic T-cell receptor (TCR) |
Hot Tags: cas 166188-11-0 tyrosinase(206-214),human, China cas 166188-11-0 tyrosinase(206-214),human manufacturers, suppliers, factory, cateninpeptide, 124454-83-7, BCMA72-80, CAS 124454 83 7, CAS 2293841 58 2, CAS 265669 37 2
